Insider trades

Anzalone Christopher Richard, CEO of Arrowhead Pharmaceuticals ARWR, has filed 0 purchases and 49 sales on the open market. Over the past 12 months that comes to a net sale of $24M. The latest trade was on 01/02.

Anzalone Christopher Richard

CEO
First filing
23/05/05
Trades
69 trades
Buys / sales
0 / 49
12-month net buying
−$24M
Last trade
01/02

Trading activity

Transactions

Trade type
ARWR
Open-market sale10b5-1 plan01/0201/0513,187 sh2 trades$66.10avg.$871,702.77−0.3%
ARWR
Open-market sale10b5-1 plan25/12/2925/12/3051,726 sh2 trades$69.13avg.$3,575,574.78−1.3%
ARWR
Open-market sale10b5-1 plan25/12/19–25/12/2225/12/2326,031 sh5 trades$68.04avg.$1,771,022.38−0.7%
ARWR
Open-market sale25/12/1725/12/1985,000 sh4 trades$64.04avg.$5,443,462.11−2.2%
ARWR
Open-market sale25/12/15–25/12/1625/12/16184,298 sh12 trades$67.00avg.$12,348,801.97−4.5%
ARWR
Open-market sale25/04/09–25/04/1125/04/11141,122 sh5 trades$10.87avg.$1,533,336.57−3.5%
Open-market sale25/03/1325/03/1751,425 sh$15.07$774,974.75−1.3%
ARWR
Open-market sale10b5-1 plan25/03/03–25/03/0425/03/05300,000 sh2 trades$17.58avg.$5,274,333.67−7.4%
Open-market sale10b5-1 plan25/01/0225/01/0611,520 sh$19.05$219,456−0.3%
Open-market sale10b5-1 plan24/12/2324/12/2312,563 sh$19.59$246,109.17−0.3%
ARWR
Open-market sale10b5-1 plan24/12/1824/12/2026,712 sh3 trades$21.24avg.$567,485.84−0.7%
ARWR
Open-market sale10b5-1 plan24/01/3124/02/0257,499 sh2 trades$32.35avg.$1,860,019.34−1.5%
ARWR
Open-market sale10b5-1 plan24/01/0224/01/049,952 sh2 trades$31.01avg.$308,636.66−0.3%
Open-market sale10b5-1 plan23/12/2023/12/2212,000 sh$28.54$342,480−0.3%
Open-market sale10b5-1 plan23/10/2523/10/2724,338 sh$24.21$589,222.98−0.6%
ARWR
Open-market sale23/09/1823/09/2057,755 sh2 trades$28.12avg.$1,624,222.64−1.5%
ARWR
Open-market sale23/05/03–23/05/0423/05/05104,928 sh3 trades$39.32avg.$4,125,673.52−2.7%